Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma.
Fiche publication
Date publication
mars 2017
Journal
Pediatric research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DEDIEU Stéphane, Pr MARTINY Laurent
Tous les auteurs :
Jeanne A, Martiny L, Dedieu S
Lien Pubmed
Résumé
We have previously identified TAX2 peptide as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with the cell-surface receptor CD47. TAX2 displays exciting antiangiogenic, antitumor, and antimetastatic properties in both allograft and xenograft models of melanoma as well as pancreatic carcinoma. Here, TAX2 therapeutic potential was investigated in two distinct preclinical mouse models of neuroblastoma.
Mots clés
Angiogenesis Inhibitors, pharmacology, Animals, Antineoplastic Agents, pharmacology, CD47 Antigen, chemistry, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Mice, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Neovascularization, Pathologic, Neuroblastoma, drug therapy, Peptides, chemistry, Peptides, Cyclic, pharmacology, Thrombospondins, antagonists & inhibitors, Treatment Outcome, Tumor Burden
Référence
Pediatr. Res.. 2017 Mar;81(3):480-488